N4-cyclopropylpyridine-2,4-diamine | 883987-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N4-cyclopropylpyridine-2,4-diamine
• 英文别名: 2-amino-4-cyclopropylaminopyridine；4-N-cyclopropylpyridine-2,4-diamine
• CAS: 883987-32-4
• 化学式: C₈H₁₁N₃
• 分子量: 149.195
• InChiKey: JMYYRFKZTJQTFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N4-cyclopropylpyridine-2,4-diamine 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 1.0h， 生成 N-cyclopropyl-2-[4-(3-fluoropropoxy)phenyl]imidazo[1,2-a]pyridin-7-amine
  参考文献：
  名称：

  [EN] 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES
  [FR] DÉRIVÉS DE 2-PHÉNYL- OU 2-HÉTARYL-IMIDAZOL[1,2-A]PYRIDINE

  摘要：

  本发明涉及式I和式II的化合物，式I或式II中，R1为氢、低级烷基、低级烷氧基、卤素、S-低级烷基、卤素取代的低级烷氧基、二-低级烷基氨基、C(O)O-低级烷基、羟基取代的低级烷基或羟基；R2为氢、低级烷基、卤素、低级烷氧基、S-低级烷基、卤素取代的低级烷氧基、O(CH2)2-卤素取代的低级烷氧基、二-低级烷基氨基、烷基氨基、NH-卤素取代的低级烷基、N(低级烷基)-苄基、羟基取代的低级烷基、任选卤素取代的杂环烷基、CH2-低级烷氧基、CH2-卤素或羟基取代的低级烷氧基；或者R1和R2与其所连接的碳原子一起形成含有-OCH2CH2O-、OCH2O-、OCH2CH2CH2O-或-NHC(O)CH2O-的环；R3为氢或低级烷氧基；R4为氢或低级烷基；R5为低级烷基、环烷基、羟基取代的低级烷基或卤素取代的低级烷基；或者R4和R5与其所连接的氮原子一起形成含有-CH2CH2CHRCH2CH2-、-CH2CHRCH2CH2-、-CH2CH2OCH2CH2-、-CH2CH2NR'CH2CH2-、CH2CHR-或-CH2CH2CH2-的环；其中R为氢、卤素、低级烷基、低级烷氧基或卤素取代的低级烷基；R'为卤素取代的低级烷基；Ra为氢或H；Rb为氢、羟基或3H；R6为氢、卤素或低级烷基；HetAr选自噻吩基、呋喃基、噻唑基、苯并呋喃基、吡唑基、苯并咪唑基或吡啶基；n为1或2；或为药学上可接受的酸加成盐、外消旋混合物或其相应的对映体和/或光学异构体。本发明的化合物适合作为成像工具，通过识别大脑中tau聚集体过量的潜在患者，将有助于改善诊断，这些患者可能发展为阿尔茨海默病。

  公开号：

  WO2014177458A1
• 作为产物：
  描述：

  2-(tert-butoxycarbonylamino)-4-cyclopropylaminopyridine 在 盐酸 、 氨 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 反应 1.0h， 以32%的产率得到N4-cyclopropylpyridine-2,4-diamine
  参考文献：
  名称：

  [EN] QUINAZOLINE DERIVATIVES
  [FR] DERIVES DE QUINAZOLINE

  摘要：

  这项发明涉及式(I)的喹唑啉衍生物或其药用盐、溶剂化合物或前药，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个在描述中已定义的含义中具有任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用于治疗细胞增殖紊乱或与血管生成和/或血管通透性相关的疾病状态的药物的用途。

  公开号：

  WO2006040520A1

文献信息

• [EN] QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER<br/>[FR] DERIVES DE QUINAZOLINE A UTILISER CONTRE LE CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2006040526A1

  公开（公告）日：2006-04-20

  The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  本发明涉及式(I)喹唑啉衍生物或其药物可接受的盐、溶剂化物或前药，其中p、R1、q、R2、R3、R4、R5、环A、X1、R6、r和R7各自具有说明书中定义的任何含义；其制备方法、含有它们的药物组合物以及它们在制造用于治疗细胞增殖障碍或治疗与血管生成和/或血管通透性相关的疾病状态的药物中的应用。
• Quinazoline derivatives for use against cancer
  申请人：Ple Patrick

  公开号：US20090036474A1

  公开（公告）日：2009-02-05

  The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R 1 , q, R 2 , R 3 , R 4 , R 5 , Ring A, X 1 , R 6 , r and R 7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  该发明涉及式（I）的喹唑啉衍生物或其药学上可接受的盐、溶剂或前药，其中p、R1、q、R2、R3、R4、R5、环A、X1、R6、r和R7中的每一个具有描述中定义的任何含义；它们的制备过程、含有它们的制药组合物以及它们在制造用于治疗细胞增殖性疾病或与血管生成和/或血管通透性相关的疾病状态的药物中的使用。
• Quinazoline derivatives
  申请人：Ple Patrick

  公开号：US20090233924A1

  公开（公告）日：2009-09-17

  The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X 1 , p, R 1 , q, R 2 , R 3 , R 4 , R 5 , Ring A, r and R 6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  本发明涉及公式（I）的喹唑啉衍生物或其药学上可接受的盐、溶剂或前药，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个都具有在本说明书中定义的任何含义；制备它们的过程，含有它们的制药组合物以及它们用于制造用于治疗细胞增殖性疾病或与血管生成和/或血管通透性相关的疾病状态的药物的用途。
• QUINAZOLINE DERIVATIVES
  申请人：Ple Patrick

  公开号：US20120165351A1

  公开（公告）日：2012-06-28

  The invention concerns quinazoline derivatives of Formula I or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X 1 , p, R 1 , q, R 2 , R 3 , R 4 , R 5 , Ring A, r and R 6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  该发明涉及公式I的喹唑啉衍生物，或其药学上可接受的盐、溶剂或前药，其中X1、p、R1、q、R2、R3、R4、R5、环A、r和R6中的每一个具有上述描述中定义的任何含义；其制备过程，含有它们的药物组合物以及它们在制造用于治疗细胞增殖性疾病或与血管生成和/或血管通透性相关的疾病状态的药物中的使用。
• 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160244441A1

  公开（公告）日：2016-08-25

  The invention relates to compounds of formulas I and II wherein R 1 is hydrogen, lower alkyl, lower alkoxy, halogen, S-lower alkyl, lower alkoxy substituted by halogen, di-lower alkyl amino, C(O)O-lower alkyl, lower alkyl substituted by hydroxy or hydroxy; R 2 is hydrogen, lower alkyl, halogen, lower alkoxy, S-lower alkyl, lower alkoxy substituted by halogen, O(CH 2 ) 2 -lower alkoxy substituted by halogen, di-lower alkyl amino, alkyl amino, NH-lower alkyl substituted by halogen, N(lower alkyl)-benzyl, lower alkyl substituted by hydroxy, heterocycloalkyl optionally substituted by halogen, CH 2 -lower alkoxy, CH 2 -lower alkoxy substituted by halogen or hydroxy; or R 1 and R 2 form together with the carbon atoms to which they are attached a ring containing —OCH 2 CH 2 O—, OCH 2 O—, OCH 2 CH 2 CH 2 O— or —NHC(O)CH 2 O—; R 3 is hydrogen or lower alkoxy; R 4 is hydrogen or lower alkyl; R 5 is lower alkyl, cycloalkyl, lower alkyl substituted by hydroxy or lower alkyl substituted by halogen; or R 4 and R 5 form together with the nitrogen atom to which they are attached a ring containing —CH 2 CH 2 CHRCH 2 CH 2 —, —CH 2 CHRCH 2 CH 2 —, —CH 2 CH 2 OCH 2 CH 2 —CH 2 CH 2 NR′CH 2 CH 2 —, CH 2 CHR— or —CH 2 CH 2 CH 2 —; wherein R is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen; R′ is lower alkyl substituted by halogen; R a is hydrogen or 3 H; R b is hydrogen, hydroxy or 3 H; R 6 is hydrogen, halogen or lower alkyl; HetAr is selected from the group consisting of thiophenyl, furanyl, thiozolyl, benzofuranyl, pyrazolyl, benzoimidazolyl or pyridinyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The present compounds are suitable as imaging tool, which will improve diagnosis by identifying potential patients with excess of tau aggregates in the brain, which may be likely to develop Alzheimer's disease.

  该发明涉及公式I和II的化合物，其中：R1为氢，低烷基，低烷氧基，卤素，S-低烷基，低烷氧基取代的卤素，二烷基氨基，C（O）O-低烷基，低烷基取代的羟基或羟基；R2为氢，低烷基，卤素，低烷氧基，S-低烷基，低烷氧基取代的卤素，O（CH2）2-低烷氧基取代的卤素，二烷基氨基，烷基氨基，NH-低烷基取代的卤素，N（低烷基）-苄基，低烷基取代的羟基，杂环烷基可选地取代卤素，CH2-低烷氧基，CH2-低烷氧基取代的卤素或羟基；或R1和R2与它们所连接的碳原子一起形成一个环，其中包含-OCH2CH2O-、OCH2O-、OCH2CH2CH2O-或-NHC（O）CH2O-；R3为氢或低烷氧基；R4为氢或低烷基；R5为低烷基，环烷基，低烷基取代的羟基或低烷基取代的卤素；或R4和R5与它们所连接的氮原子一起形成一个环，其中包含-CH2CH2CHRCH2CH2-、-CH2CHRCH2CH2-、-CH2CH2OCH2CH2-CH2CH2NR′CH2CH2-、CH2CHR-或-CH2CH2CH2-；其中R为氢，卤素，低烷基，低烷氧基或低烷基取代的卤素；R′为低烷基取代的卤素；Ra为氢或3H；Rb为氢，羟基或3H；R6为氢，卤素或低烷基；HetAr选自噻吩基，呋喃基，噻唑基，苯并呋喃基，吡唑基，苯并咪唑基或吡啶基；n为1或2；或其药学上可接受的酸加成盐，其外消旋混合物或其对应的对映异构体和/或光学异构体。这些化合物适用于成像工具，通过识别大脑中tau聚集过多的潜在患者，有助于改善诊断，这可能会导致阿尔茨海默病的发展。